Video call or Face-to-Face? study tests which genetic counselling works best
NCT ID NCT04738708
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares genetic counselling done by video (telegenetics) with traditional in-person sessions for people at risk of hereditary breast, ovarian, or colorectal cancer. Researchers will measure how well patients understand their options, their emotional responses, and the overall cost. The goal is to see if video counselling is a good alternative that saves time and money.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could show that telegenetics is as effective as in-person counselling, making genetic counselling more accessible and cheaper for patients.
- What could go wrong
- This is a small, early-stage study (150 participants) comparing two counselling methods, not testing a new treatment. Results may not apply to all populations or settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 150 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Feb 2021
- Expected to finish
-
Oct 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients referred to CGS at NCCS for HBOC or Lynch syndrome pre-test genetic counselling.
- Ages
-
21 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age ≥ 21 years old. * Patients referred to CGS at NCCS for HBOC or Lynch syndrome pre-test genetic counselling. * Able to read and understand the English Language. * Able to consent and agree to be randomized to either telegenetics or in-person genetic counselling. Exclusion Criteria: * Under the age of 21 years old. * Patients who require genetic results urgently. * Cognitive difficulty/ impairment or current psychiatric or physical illness (visual/ hearing/ neurological) which impairs sound judgement and accurate reporting of medical history over video consultation.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Genetic counselling are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
National Cancer Centre Singapore
RECRUITINGSingapore, 169610, Singapore
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A watchful eye: could alternating scans outsmart pancreatic cancer?
- Beyond BRCA: new gene panel could sharpen cancer risk prediction
- Can a walking routine alter cancer biomarkers? new trial investigates
- Digital assistant aims to close gaps in hereditary cancer care
- Lynch syndrome patients share colonoscopy struggles in new survey
- Personalized vaccine aims to stop lynch syndrome cancers before they start